Inclusion Criteria:

1. Patients must have cytologic or histologic proof of large (>5 mc), Grade III,
resectable soft tissue sarcoma of the extremity or trunk (AJCC Stage IIIB). Patients
with The American Joint Committee on Cancer (AJCC) Stage IIB tumors (Grade II)
greater than 8 cms will also be eligible.

2. Patients may have measurable or non-measurable disease (C/P pre-referral excision).

3. Patients may have had prior doxorubicin (up to a total doxorubicin dose of 450
mg/m2).

4. Patients may have a prior history of malignancy (at the discretion of the Principal
Investigator).

5. Patients must have Karnofsky Point Scale (P.S.)> of >70 or Xubrod P.S. of 0 or 1.

6. Patients must have: Absolute neutrophil count (ANC) > 1,500 cells/mm; platelet count
> 100,000 platelets/ml; serum creatinine <1.8 mg/dl, aspartate aminotransferase (AST
or SGOT) and alanine aminotransferase (ALT or SGPT) < 3 times normal, total bilirubin
< 1.5mg/dl; for patients with cumulative Adriamycin 450 mg/M2, EF >50%.

7. Women of childbearing potential must not be pregnant or breast feeding and must
practice adequate contraception.

Exclusion Criteria:

1. Patients must not have had prior radiation therapy (XRT) in the area of the primary
tumor, and the anticipated XRT field must not include the perineum, scrotum, or
vaginal introitus.

2. Patients with uncontrolled coexisting medical conditions are excluded.

3. Patient must not be pregnant or brest feeding.